For decades Tumor Necrosis Factor (TNF)-α  inhibitors have been a mainstay of systemic plaque psoriasis therapy for over a decade. DLX-105 will be the first TNF-a inhibitor administered intradermally directly onto psoriatic plaques. Activity from DLX-105 is restricted to the plaque site without affecting systemic immunity. It is the novel method of self-administration through micro needles that makes this local effect possible (see the illustrations below).

Arrivo is currently conducting an open label Phase 1b study in patients with mild to moderate plaque psoriasis.

DLX-105 Micro Array Patch Delivery

DLX-105 Antibody Description